The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 27, Digger (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH)) submitted a listing application to the main board of the Hong Kong Stock Exchange, with Goldman Sachs and Huatai International as co-sponsors. The company submitted a listing application to the Hong Kong Stock Exchange on January 23. According to the prospectus, Dizhe Pharmaceutical is a biopharmaceutical company in the commercialization stage. The company's core treatment areas are tumors and hematological diseases. During the track record period, Dizhe Pharmaceuticals developed and commercialized golixitinib (Gaolizhe®), a next-generation highly selective Janus kinase 1 (“JAK1”) inhibitor in mainland China. Additionally, Dizhe Pharmaceutical developed, commercialized, and externally authorized Schwarzer®, the world's first small molecule epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) approved for the treatment of EGFR exon 20 (“exon20ins”) mutant lung cancer.

The Zhitong Finance App learned that according to the Hong Kong Stock Exchange's disclosure on August 27, Digger (Jiangsu) Pharmaceutical Co., Ltd. (688192.SH)) submitted a listing application to the main board of the Hong Kong Stock Exchange, with Goldman Sachs and Huatai International as co-sponsors. The company submitted a listing application to the Hong Kong Stock Exchange on January 23. According to the prospectus, Dizhe Pharmaceutical is a biopharmaceutical company in the commercialization stage. The company's core treatment areas are tumors and hematological diseases. During the track record period, Dizhe Pharmaceuticals developed and commercialized golixitinib (Gaolizhe®), a next-generation highly selective Janus kinase 1 (“JAK1”) inhibitor in mainland China. Additionally, Dizhe Pharmaceutical developed, commercialized, and externally authorized Schwarzer®, the world's first small molecule epidermal growth factor receptor (“EGFR”) tyrosine kinase inhibitor (“TKI”) approved for the treatment of EGFR exon 20 (“exon20ins”) mutant lung cancer.